Subcutaneous · GLP-1 / GIP / glucagon triple
HRS-4729 / KAI-4729
5 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
5
Ongoing
4
Recruiting
2
Completed
1
Sites
7
Countries
1
Endpoints
44
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Phase 2
3
Trials by status
Not yet recruiting
2
Recruiting
2
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
20
Weight & body composition
8
Glycemic / diabetes
7
MASH / liver
5
Cardiometabolic biomarkers
3
Other (unclassified)
1
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
1
CmaxSafety/PK
1
TmaxSafety/PK
1
Half-lifeSafety/PK
1
Immunogenicity (ADA)Safety/PK
1
Body weight, absolute change (kg)Weight
1
Fasting glucose, changeGlycemic
1
Total fat massWeight
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
5 of 5
Showing 1-5 of 5 trials